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OBJECTIVES The AtheroLink registry sought to observe the effect of plaque burden reduction by
directional coronary atherectomy (DCA) prior to stenting on acute lesion success rate, on the
clinical success rate and on the incidence of in-stent restenosis six months after intervention.
BACKGROUND Although coronary stenting has reduced restenosis, its effect has been less favorable in
complex lesions with a high plaque burden that results from suboptimal stent expansion.
Therefore, plaque removal by DCA may improve the results of coronary stenting.
METHODS A total of 167 patients with .60% stenosis in a native coronary artery of 2.8 to 4.0 mm in
diameter were enrolled in 10 study centers on an intention-to-treat basis. All patients
underwent DCA aimed at an optimal result (residual diameter stenosis ,20%) followed by
stenting. Angiographic follow-up was performed in 120 (71.8%) patients at 5.3 6 2.8
months.
RESULTS Lesion success was achieved in 164/167 (98.2%) patients, and the clinical success rate was
95.2% (159/167 patients). The overall restenosis rate in the 120 patients with angiographic
follow-up was 10.8% (13/120). Incidence of restenosis was lower (8.4%) in patients with
optimal stent deployment following DCA compared to patients with a persisting caliber
reduction .15% (restenosis rate 15.3.%) and restenosis occurred with a significantly higher
frequency (p , 0.04) in distal lesions (37.5%) compared to proximal stenoses (9.0%).
CONCLUSIONS This observational multicenter registry points to a potential reduction in restenosis by a
synergistic approach of DCA and stenting performed under routinely accessible angiographic
guidance. Therefore, multicenter-based randomized clinical trials are clearly warranted to
finally clarify the validity of this complex approach versus conventional angioplasty plus
stenting. (J Am Coll Cardiol 2000;36:1853–9) © 2000 by the American College of
Cardiology
Although coronary stenting has significantly reduced steno-
sis (1,2) its effect has been less favorable in more complex
stenoses (3) and in lesions with a high plaque burden, which
limits optimal stent expansion and may additionally con-
tribute to the induction of intimal hyperplasia after stent
implantation (4). In addition, data from intravascular ultra-
sound (IVUS) studies indicate that in-stent restenosis has a
tendency to occur at the original lesion site where the plaque
burden is usually largest (5). Therefore, plaque removal
prior to stent implantation could be a clinically feasible
approach to further improve acute and long-term results of
stent deployment. Directional coronary atherectomy (DCA)
as a tool for debulking obstructive coronary lesions was
originally developed as a potential replacement for stand-
alone balloon angioplasty (percutaneous transluminal coro-
nary angioplasty [PTCA]) (6). However, the results of early
randomized studies comparing PTCA and DCA were
unexpectedly disappointing since they demonstrated that
DCA was associated with a higher incidence of death and
myocardial infarction than PTCA and yielded similar re-
stenosis rates despite the removal of plaque material (7,8).
In contrast, Baim et al. (9) could show in a recently
published study that a technically optimized DCA proce-
dure achieved a larger initial lumen and a higher procedural
success rate than PTCA, without an increased risk of death,
Q-wave myocardial infarction and need for coronary artery
bypass surgery. Furthermore, DCA resulted in a lower rate
of restenosis than did PTCA. However, the challenge of
DCA today is not to be better than PTCA but to be better
than PTCA plus stenting, a goal that may be achieved by
optimal preparation of the vessel before stent deployment in
terms of plaque removal using DCA.
Moussa (10) et al. recently demonstrated in a monocen-
tric evaluation that such a reduction of plaque burden by
DCA with subsequent stenting of the respective lesion can
be performed with a high clinical success rate (96%) and
strikingly low incidence (11%) of angiographic restenosis at
six months’ follow-up. In the present study we tried to
confirm these promising results by a nonrandomized, open
multicenter approach (AtheroLink registry), which was
chosen to assess the clinical and lesion success rate of DCA
plus stenting and to evaluate the incidence of stent reste-
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nosis with respect to individual coronary arteries and the
localization of the target lesion after a six-month follow-up
period.
METHODS
Center selection. Special care was taken to select centers
with current DCA experience. All operators must have
performed at least 25 DCA procedures and 10 within the
year of study onset. The main principles of the AtheroLink
registry were 1) to remove as much tissue as considered safe
by the operator; 2) to obtain a final residual stenosis ,20%
after DCA whenever possible; and 3) to complete the
procedure by optimal stent deployment (residual diameter
stenosis ,15%) by use of a Multilink stent. Use of IVUS
was allowed but neither encouraged nor required (15% of
the enrolled patients).
Study design and patient selection. The AtheroLink
registry is a prospective, nonrandomized, open multicenter
observation of patients undergoing DCA prior to stenting.
Eligible patients were invited to participate in the trial, and
informed consent was obtained under a protocol approved
by the institutional review board at each participating
center. Between January 1997 and June 1998, a total of 167
patients were recruited on an intention-to-treat basis ac-
cording to the following predetermined criteria: 1) clinical
or functional evidence of myocardial ischemia; 2) no myo-
cardial infarction within 72 h, cardiogenic shock, or bail-out
situations (i.e., threatened or abrupt closure after a previous
interventional approach); 3) all the following: vessel size by
quantitative coronary angiography (QCA) 2.8 to 4.0 mm,
diameter stenosis $60% or $50% in highly eccentric
lesions; lesion length ,30 mm, no in-stent restenosis, no
moderate to severe calcification proximal to the target
lesion, no bifurcational lesions with a side branch of $2 mm
by means of QCA. Patients with ostial lesions, restenotic
lesions, and lesions requiring a preintervention in order to
perform DCA (e.g., chronic total occlusions) were consid-
ered for enrollment.
Detailed case report forms concerning baseline demo-
graphic and clinical data, procedural details, and in-hospital
outcome (including routine ascertainment of CK [creatine
kinase] and CK-MB [CK-MB fraction] before treatment
and 12 to 24 h after intervention; further determinations
were required if either CK or CK-MB was elevated) were
completed after the procedure, at hospital discharge and at
six-month follow-up by the clinical coordinator at each site
and were submitted to the data coordinating center.
Analysis of cineangiograms was performed at each par-
ticipating center by computer-assisted analysis (QCA with
digital coronary imaging by Philips and CAAS/II by
Piemedica) and these data were forwarded to the study
coordinating center. Lesions were classified with respect to
the American College of Cardiology/American Heart As-
sociation classification (11). Prior to any QCA measure-
ment, intracoronary application of 200 mg nitroglycerin was
mandatory. Quantitative analysis of coronary angiography
in one optimal view was required, and this view was
preferably used for all QCA measurements, including the
follow-up angiography. However, the view demonstrating
the highest grade of stenosis in each step was more relevant.
Proximal and distal reference diameter (RfD), minimal
lumen diameter (MLD), and % stenosis were determined by
QCA using the contrast-filled injection catheter as the
calibration standard. Based on QCA analysis, lesion success
was defined as the ability to reduce lesion severity by DCA
and stenting with a final result of ,50% diameter stenosis.
The clinical success rate was defined as MLD ,50% of
reference, no in-lab or in-hospital non-Q-wave or Q-wave
myocardial infarction as defined by new appearance of signif-
icant Q waves in a minimum of two leads, urgent bypass
operation, or death within the subacute phase (days 1–7).
Clinical and angiographic follow-up was obtained rou-
tinely at six months, unless earlier follow-up was required
for clinical reasons. The prespecified primary end point was
angiographic restenosis (diameter stenosis of the target
vessel $50%). Secondary end points included short-term
lesion and clinical success, procedural safety, acute and
subacute stent thrombosis, in-hospital non-Q-wave infarc-
tion (any CK-release and/or CK-MB release .3 times the
upper limit of the individual laboratory without Q waves),
intraaortic balloon pump or ReoPro usage to prevent acute
or subacute stent thrombosis and clinical restenosis surro-
gates.
DCA and stent implantation. Directional coronary
atherectomy was performed by use of the Simpson Athero-
cath (Devices for Vascular Interventions) as previously
described (12). Predilation procedures were at the operator’s
discretion. The aim was to achieve a residual diameter
stenosis ,20% confirmed with QCA by multiple cuts,
which were performed by a maximum inflation of 4 bar. At
the end of the procedure, removed bulk was semiquantita-
tively evaluated using the following scale: 0 5 no material;
1 5 some pieces of material; 2 5 sufficient amount of
material relative to plaque burden, but not all tissue re-
moved; 3 5 almost all tissue removed.
Coronary stenting was performed with multicellular
stents (Multilink, Guidant Corp.) aiming at an optimal
result (MLD .distal reference diameter and MLD .prox-
imal reference diameter minus 15%). For initial stent
deployment an inflation pressure of 8 bar was used with the
option of further inflations to optimize angiographic results
Abbreviations and Acronyms
CK-MB 5 creatine kinase-MB fraction
DCA 5 directional coronary atherectomy
IVUS 5 intravascular ultrasound
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
QCA 5 quantitative coronary angiography
RfD 5 reference diameter
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by using a short high-pressure balloon. A stepwise pressure
application with the short balloon positioned within the
stented area was recommended with the following steps:
10-12-14-16 and .16 bar.
Preinterventional and postinterventional management.
All patients were pretreated with aspirin (100 to 500 mg)
once a day and ticlopidine (250 to 500 mg) twice a day
.48 h before interventional procedures. Ticlopidine was
given for at least two to four weeks and aspirin for at least
six months after intervention.
Statistical analysis. Continuous variables were expressed
as mean values 6 1 SD. Categorical variables were com-
pared by chi-square analysis. Analysis of variance (repeated
measures ANOVA using SPSS 9.0 for Windows with a
multiple comparison procedure and Bonferroni correction)
was performed on preinterventional, postinterventional and
follow-up QCA data with respect to the RfD, MLD, and
diameter stenosis. The null hypothesis was rejected at the
95% confidence level, considering a p value ,0.05 as
statistically significant.
RESULTS
Patient characteristics. Of 167 patients (128 men [77%],
39 women [23%]; mean age: 55.8 6 18.8 years; previous
myocardial infarct: 45%; left ventricular ejection fraction
,35%: 7%; triple vessel disease: 19%) who were initially
enrolled on an intention-to-treat basis, 120 patients (71.8%)
completed the entire study protocol. Of the remaining 47
patients, 3 patients (1.8%) died within the study period, 3
more (1.8%) had unsuccessful DCA, 17 patients (10.2%)
had a premature angiographic follow-up and/or additional
revascularization procedures due to angina or infarction, and
24 patients (14.4%) did not return for control coronary
angiography. Most of these patients (21/24) had a clinical
follow-up, but three patients could not be contacted within
the control period. A flow-sheet demonstrating the patient
recruitment until the final evaluation including angiographic
follow-up is summarized in Figure 1. Baseline and angio-
graphic characteristics of the patients with a complete
follow-up are presented in Table 1.
Procedure performance. In 164 of 167 patients, DCA was
performed using 13 6 7 cuts per lesion. In the other three
patients the DCA device could not be adequately positioned
in the lesion area owing to extreme tortuosity proximal to
the target lesion. In these three patients conventional
PTCA with additive stenting in one patient was successfully
performed. In 64% of procedures, final device size was 7F.
A 6F cutter was used in the remaining 36% of procedures.
Optimal DCA (residual diameter stenosis ,20% by QCA)
was achieved in 71 (59%) lesions. Semiquantitative estima-
tion of the total material removed by DCA yielded the
following results: grade 0 (3%), grade 1 (2%), grade 2 (26%),
grade 3 (69%).
The length of implanted stents was 15 mm in 69%,
25 mm in 26% and 35 mm in 5% of stent deployments. The
balloon size was 3.0 mm in 24%, 3.25 mm in 2%, 3.5 mm
in 56%, and 4.0 mm in 18% of interventions. The mean
maximal inflation pressure was 12 6 3 bar. A total of 13
Figure 1. Flowchart characterizing the study population, observation periods and related clinical complications, frequency of restenosis and need of target
lesion revascularization.
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patients (10.8%) received two or more stents following
DCA.
Short-term results and procedural complications. In 164
of 167 patients the combined approach of DCA and stenting
could be successfully performed, resulting in an initial lesion
success rate (posttreatment diameter stenosis ,50%) of 98.2%.
There were no patients who underwent DCA and stenting in
more than one lesion. Two patients (1.2%) developed a vessel
perforation at the site of atherectomy, a situation that could be
controled by stent deployment.
In the subacute phase (days 1 to 7), four patients (2.4%)
developed a non-Q-wave and one patient (0.6%) a Q-wave
myocardial infarction. Consequently, the clinical success
rate was 95.2% (159/167 patients). No patient developed
acute or subacute stent thrombosis or was additionally
treated with glycoprotein IIb/IIIa receptor blocking agents.
In the follow-up period (5.3 6 2.8 months) major
complications included 1 cardiogenic death (0.6%), 4 bypass
operations (2.3%), 2 Q-wave myocardial infarctions (1.1%),
and 6 non-Q-wave myocardial infarctions (3.6%). Two
patients (1.3%) died of noncardiac reasons during the
control period. Clinical success rate, including all events
during the acute, subacute and follow-up period and exclud-
ing those three patients who did not come to a clinical or
angiographical follow-up, was 85.9% (141/164).
Overall incidence of restenosis and target lesion revas-
cularization. Angiographic follow-up was performed in
120/167 (71.8%) patients. The QCA measurements before
intervention, after DCA, after stenting and at control
coronary angiography of the 120 patients with complete
follow-up are demonstrated in Table 2. Angiographic re-
stenosis was found in 13 of 120 lesions (10.8%). The
incidence of restenosis was lower in patients with optimal
stenting by QCA (8.4%) compared to patients in whom
optimal stenting could not be achieved (restenosis rate 5
15.3%). Restenosis was detected in 10.3% of de novo lesions
and in 15.4% of restenotic lesions. In the 13 vessels with
restenosis, target-lesion revascularization was mandatory in
9 lesions—that is, a target-lesion revascularization rate of
7.5% with respect to the 120 angiographically controlled
patients. In the subset of patients with diabetes (n 5 14), no
restenosis could be detected.
Incidence of restenosis with respect to the vessel size.
The relation between vessel size and restenosis rate was
analyzed by assigning vessels from 2.8 to 3.0 mm (n 5 62),
3.1 to 3.5 mm (n 5 42) and 3.6 to 4.0 mm (n 5 16) to
various categories. The different incidence of restenosis in
these three vessel-size categories did not reach the level of
significance (16.1% for vessels ranging from 2.8 to 3.0 mm;
7.1% for vessels ranging from 3.1 to 3.5 mm, and 6.2% for
vessels ranging from 3.6 to 4 mm; p 5 NS for the
comparison of all categories). However, there was a ten-
dency toward a higher restenosis rate (16.1%) in smaller
vessels (vessel size 2.8 to 3.0 mm).
Incidence of restenosis with respect to individual coro-
nary arteries and lesion location within the vessel. Inci-
dence of restenosis was not significantly different for left
anterior descending, left circumflex, and right coronary
artery (9.7% vs. 11.1% vs. 12.8%, respectively). In contrast,
the site of the lesion had a significant influence on the
incidence of restenosis. Restenosis rate was significantly
higher (p , 0.04) in distal lesions (37.5%) compared to
lesions located in the mid- (8.8%) or proximal (9.0%) aspect
of a particular coronary vessel.
Table 1. Baseline and Angiographic Characteristics of Patients With Postinterventional Angiographic Follow-up
Patients (n 5 120) Risk Factors Lesions
Age (yrs) 51.9 6 23 Smoking 65 (54%) LAD 72 (60%)
Men 98 (83%) Hypertension 74 (62%) LCX 9 (7.5%)
Unstable angina 40 (33%) Diabetes 14 (12%) RCA 39 (32.5%)
LVEF ,35% 10 (8%) Hyperlipidemia 90 (75%) Proximal 78 (65%)
Multivessel disease 22 (18%) Family history 56 (47%) Mid 34 (28%)
Previous PTCA 63 (53%) Distal 8 (7%)
Previous CABG 13 (11%)
Previous infarct 63 (53%)
LAD 5 left anterior descending coronary artery; LCX 5 left circumflex coronary artery; LVEF 5 left ventricular ejection fraction; RCA 5 right coronary artery.







Rfd (mm) 3.5 6 0.8 3.8 6 0.6 3.4 6 0.9
MLD (mm) 1.0 6 1.0 3.6 6 0.6* 3.1 6 1.1
Diameter stenosis (%) 76.2 6 12.5 5.4 6 6.6* 23.6 6 20.1**
Values shown for reference diameter (Rfd), minimal lumen diameter (MLD), and diameter stenosis based on quantitative
coronary angiography (QCA) analysis are the mean 6 SD. Significant differences are indicated: *p , 0.01 for preintervention
versus post-DCA and stenting and **p , 0.01 for post-DCA and stenting versus six-month angiographic follow-up.
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DISCUSSION
Clinical background for a synergistic strategy of DCA
and stenting. Stent deployment is associated with a dra-
matic decline in acute complication rates after angioplasty,
and it proved to reduce the incidence of restenosis as
demonstrated in the STRESS (13) and BENESTENT (1)
studies. However, it is important to consider that the
particular benefit of stent implantation in lesions with
complex characteristics that, by design, were excluded from
STRESS and BENESTENT, such as long lesions requir-
ing multiple stents, lesions involving vessel ostia or bifurca-
tions, and lesions in smaller vessels or distal locations, has
not been confirmed in a randomized fashion. For example,
in a series of 700 consecutive patients with 745 lesions
treated with coronary stents, Sawada et al. (14) found that
only 20% of the lesions would have been eligible for
inclusion in STRESS and BENESTENT. Although the
six-month restenosis rate in this series was 11% for
STRESS/BENESTENT equivalent lesions, restenosis oc-
curred in .30% of lesions that would have been excluded
from these randomized trials.
In a separate series, among 522 consecutive patients in a
multicenter registry who underwent stent implantation, only
7% would have qualified for enrollment in STRESS/
BENESTENT (15). These observational reports suggest
that when applied to a less selected group of patients than
those studies in the randomized trials, the relative advan-
tages of stent implantation with respect to the incidence of
restenosis may be significantly attenuated. Therefore, a
synergistic interventional concept like plaque debulking
prior to optimal stent deployment may be promising with
respect to a further reduction of restenosis.
Study findings. The underlying concept of the AtheroLink
registry was to observe whether debulking of coronary
lesions by DCA prior to stenting performed on a multi-
center basis under angiographic guidance alone may be an
effective and clinically safe approach for the prevention of
restenosis. In fact, the principal finding of this multicenter
registry is that the synergistic approach of DCA and
stenting was associated with a high lesion (98.2%) and
clinical success rate (95.2%) and a low incidence of overall
angiographic restenosis (10.8%) after six-months’ follow-
up, which is obviously lower than restenosis rates reported
from stent trials without control by intravascular ultrasound
(1,13). Furthermore, restenosis rates were not significantly
different between lesions assigned to specific coronary ar-
teries but yielded a significant difference with respect to
stenosis localization—that is, distal stenoses had a signifi-
cantly higher incidence of restenosis than did lesions in the
mid- and proximal aspect of the respective vessel. Although
the analysis of vessel size with respect to the incidence of
restenosis did not yield a significant difference for the three
vessel-size categories, ranging from 2.8 mm to 3.0 mm, 3.1
to 3.5 mm, and 3.6 to 4.0 mm, there was a tendency toward
a higher incidence of restenosis in vessels ranging from 2.8
to 3 mm. This finding is in agreement with an observational
study of Savage et al. (3), who reported that the incidence of
restenosis following stent deployment in smaller coronary
vessels is significantly greater than in discrete lesions of
larger coronary arteries. The QCA analysis showed that the
magnitude of acute gain after stent deployment was identi-
cal (2.6 mm for SOLD and AtheroLink registry) with a
lower late loss for the AtheroLink registry (0.5 mm vs.
0.91 mm). A case example of combined DCA and stenting
of the right coronary artery is shown in Figure 2.
Comparison with previous studies. In a recently pub-
lished monocenter study, Moussa et al. (10) included 71
patients in a prospective registry to establish whether plaque
removal by DCA before stent deployment would improve
long-term patency beyond what is achievable by stent
implantation alone. Similar as in the present study, all
patients, most of them with higher lesion complexity,
underwent elective intervention. In both studies the syner-
gistic interventional approach was safe. Major cardiac events
Figure 2. (Left panel) Baseline angiogram of the right coronary artery showing a lesion in the pars descendens of the vessel. (Middle left panel) Post-DCA
angiogram showing a slight caliber reduction in the lesion area. (Middle right panel) Post-STENT angiogram. (Right panel) Coronary angiogram at
five-month follow-up.
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(cardiogenic death, Q-wave myocardial infarction, or the
need for reintervention or bypass grafting) occurred in 4.2%
of patients in the SOLD registry versus 4.1% in the present
study. These results are comparable to the STRESS study
(13) with major cardiac events reported from 4.9% of
patients at 30 days. The occurrence of non-Q-wave myo-
cardial infarction, which was defined as elevation of cardiac
enzymes to more than twice normal, was reported as 11.3%
of patients in the SOLD registry compared to a lower rate
of 5.4% in the present study. The lower incidence of
non-Q-wave myocardial infarction in the present trial may
be related to differences in the patient populations and a
different definition threshold for non-Q-wave infarcts. The
SOLD registry enrolled 56% of patients with multivessel
disease, in contrast to 18% of patients with two or more
stenosed vessels included in the AtheroLink registry. More-
over, in the SOLD registry 13 patients (21%) had more than
one lesion, which was treated by DCA and stenting, in
contrast to the AtheroLink registry, which had only one
treated lesion per patient.
Clinical success was higher in the AtheroLink registry
(95.2%) and almost identical to what was reported from the
SOLD registry (96%). Angiographic follow-up in the
SOLD registry was performed in 62/70 (89%) eligible
patients and showed a remarkably low angiographic resten-
osis rate of 10.7%, with a need for target-vessel revascular-
ization in only 6.7% of patients. Restenosis rate and target-
vessel revascularization were significantly lower compared to
a stent-alone group (matched comparison) in the SOLD
registry. Almost identical results could be achieved in the
present multicenter approach, with an overall angiographic
restenosis rate of 10.8% (13/120 lesions), although angio-
graphic guidance was used for DCA and stenting in contrast
to the SOLD registry, which was additionally based on
intravascular ultrasound guidance. Target-lesion revascular-
ization was required in 7.5% of patients. A matched
comparison was not performed in the present study; how-
ever, a comparison of the data with retrospectively evaluated
stent-alone patient populations with heterogeneous stenosis
morphology (inclusion of long and complex lesions) shows
a striking reduction of restenosis rate and target-lesion
revascularization. Mehran et al. (16) reported a restenosis
rate of 22% after stenting of discrete lesions and 28%
restenosis rate in lesions .15 mm.
Angiographic restenosis was detected in 10.3% of de novo
lesions and in 15.4% of restenotic lesions. A similar obser-
vation was made by Kornowski et al. (17), who reported on
the clinical outcome of patients who had stent implantation
in 3.25-mm vessels. In that trial, the need for target-lesion
revascularization was lower in de novo than in restenotic
lesions (14% vs. 22%, respectively). However, it should be
mentioned that follow-up in this patient population was
based on clinical findings that may lead to underestimation
of the incidence of significant luminal renarrowing.
Effectiveness of DCA and stenting for the prevention of
restenosis. In the SOLD registry, differentiation of the
study population in two groups with respect to the plaque
burden at the lesion site after DCA expressed as percent
plaque area suggests that more aggressive debulking leads to
further reduction in late lumen loss and restenosis. In the
present study, debulking was evaluated in a semiquantitative
fashion. Although almost all tissue (grade 3) could be
removed by DCA in most of the patients, we could not
demonstrate a significant difference between the incidence
of restenosis for the combined grades 0 to 2 (37 patients 5
30%) versus grade 3 (83 patients 5 70%). This observation
may be explained by the low absolute number of restenoses
(n 5 13) and the semiquantitative estimation of the re-
moved material, which was not assessed in relation to the
total plaque burden. Assessment of total plaque burden by
IVUS in relation to the amount of removed material by
DCA would have been a more appropriate approach to
analyze the relation between debulking and the incidence of
restenosis. However, the concept of the present study was
based on a routinely achievable angiographic guidance of the
combined DCA and stenting procedure. In contrast to the
semiquantitatively evaluated debulking effect of DCA, the
achievement of optimal stenting controled by QCA showed
a tendency of reduced restenosis compared to suboptimal
stenting (10% vs. 18%). Moreover, smaller vessels by QCA
(2.8 to 3 mm) had a strong tendency toward a higher
incidence of restenosis (16.1% vs. 6.2%) compared to larger
vessels (3.6 mm to 4.0 mm).
Study limitations. One study limitation that merits com-
ment is the number of patients (24/167 patients; 14.4%)
who did not comply with the preestablished study protocol,
and for which they had given written consent. To compen-
sate for this noncompliance, we tried to collect clinical data
on an outpatient basis. A subgroup of 12 patients was free of
angina and had no exercise-inducible angina. Nine patients
could be reached by telephone interview and reported to be
free of angina. Three patients could not be evaluated
because they moved to their country of origin. Thus, a
clinical follow-up in 21/24 (87%) patients could be
achieved.
Another study limitation is the fact that the concept of
this multicenter registry was primarily based on a local QCA
analysis by each participating center, which was controled
by the study coordinating center. However, the QCA
measurements were performed by different operators, which
could have influenced the results.
Conclusions. The synergistic approach of DCA and stent-
ing performed on a multicenter basis yielded encouraging
data with respect to a potential reduction of angiographic
restenosis and the reduced need for repeated target-vessel
revascularization in a selected patient population. This is in
good agreement with a previously reported monocenter
registry on the combined use of DCA and stenting (10).
Because the efficacy of repeat angioplasty for the treatment
of in-stent restenosis appears to be poor (18,19), potentially
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effective, safe and predictable strategies for prevention of
in-stent restenosis like the use of DCA before stenting
should be evaluated further. The open question is whether
DCA plus stenting proves superior to stenting alone with
respect to the incidence of restenosis; this will be addressed
by a prospective randomized multicenter study (Atherec-
tomy before Multilink Improves Lumen gain and Clinical
Outcomes [AMIGO]). The result of this study will show
whether DCA will remain alive as a preparative tool for
optimal stenting or will further decline to an infrequently
used “niche” technique for the treatment of ostial stenosis or
cellular studies on plaque composition.
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